

## Q2/2023 Venture Report

## Medical Alley Venture Report

The Medical Alley Venture Report is a quarterly analysis of investment, M&A and other factors driving growth in Medical Alley<sup>®</sup>, the epicenter of health innovation and care<sup>®</sup>.

If you're leading a startup, managing acquisitions, or looking to invest in one of the world's leading health innovation ecosystems – contact <u>Filip Kostal</u> or <u>Kylle Jordan</u>.



**Medical Alley** 



### **Medical Alley Starts**

Venture platform to lower the cost of starting, scaling and pivoting new ventures



Bringing Medical Alley to the world and the world to Medical Alley



#### **Global Investor Network:**

Connecting startups to investors from pre-seed to growth.



#### **Global Corporate Partner Network:**

Facilitating partnership, M&A, JVs and other engagements with global leaders in healthcare



#### **Ready Reserve Entrepreneur Volunteers:**

A network of experienced entrepreneurs ready to lend their expertise to your venture



### **Medical Alley Starts – Q2/2023**





Served 347 companies and delivered;

39

Investor introductions

**132** 

Supplier connections

**70** 

Corporate development connections

123

Peer connections



**184 stories shared** through Medical Alley channels



### Q2/2023 – Key Takeaways

- Medical Alley companies continue to perform well compared to other industries, recording a 56% increase in private investments over last year, and attracting more than \$1.1 billion overall in the first half of the year, 42% more than during H1 of last year. For comparison, other global and local investments are down (18% and 63% respectively).
- Late-stage and growth rounds continue to be the main dollar drivers, but deal volume increased 35% over the previous quarter, showing signs of improvement for early stage.
- Saluda Medical's \$150 million raise was the second largest private raise of the year only behind Gravie's \$179 million growth round from Q1.
- Our analysis showed three secondary offerings, indicating that while public market activity may have decelerated, an accessible pool of capital remains.
- SBIR/STTR funding dipped compared to last quarter, but the overall trend is positive.



# \$713 Million Raised by Medical Alley Companies

- Medical Alley companies raised more than \$713 million in Q2/2023.
- Venture funding was the largest contributor in Q2/2023, as companies raised more than \$434 million, 56% more than last quarter, and almost 2.5x as much as in Q2/2022.
- There was a variety of activity in the public markets with three very different transactions taking place.
- SBIR/STTR funding was down slightly, but the overall numbers continue to be trending up compared to past years.

Q2/2023 Startup Funding		
Private Capital	\$434,061,368	
Public Capital	\$273,750,000	
SBIR/STTR	\$5,485,637	
Total \$713,297,005		



#### **Startup Funding – H1/2023**

# More than \$1.1 Billion Raised, Medical Alley Companies Are Not Slowing Down

- In a challenging environment, Medical Alley companies raised almost \$1.18 billion dollars in H1/2023, 42% more than during the first half of last year.
- Growth deals contributed most to the \$711 million of private capital raised. Gravie (\$179 million) and Saluda Medical (\$150 million) were the two largest private raises.
- Medical Alley companies more than tripled last year's amount of money raised in the public markets.
- SBIR/STTR funding was on par with last year in H1/2023.

H1/2023 Startup Funding		
Private Capital	\$711,861,271	
Public Capital	\$394,029,500	
SBIR/STTR	\$12,303,181	
Total \$1,118,193,952		



# Private Funding – Q2/2023 Not Following Global Trends

While venture funding in Minnesota in general is down by 63%<sup>1</sup>, the \$434 million of private capital invested in Medical Alley is the highest since Q1/2022 and an 87% increase over Q1/2023.

Digital health funding decreased by 18% Q-o-Q; however, medical device companies recorded the largest amount raised since Q1/2022.

\$236,517,165
Medical device

\$152,704,574

Digital health

\$29,699,629
Biopharma

\$15,000,000 Provider



## Private Funding – Q2/2023 Not Following Global Trends

- The 27% Q-o-Q increase in average deal size is continuing the trend of latestage deals inflating the overall volume. Saluda Medical's \$150 million round, Flywheel's \$54 million Series D, and Relievant Medsystems' \$50 million Series G were the three largest publicly announced private transactions.
- Even the number of deals increased in Q2/2023 27 individual companies reported raising capital, 7 more than last quarter.
- Given Q3 typically presents softer results, a clearer indication of the market's potential improvement will be assessed in Q4 performance.



## Public Markets – Q2/2023 \$273.75 Million in Public Markets

- The \$273.75 million raised in public markets was the largest amount raised since Q4/2021, and a marked increase over last quarter's \$120 million.
- The three deals were very different in nature. Lifecore secured the funds from one investor, ANI Pharmaceuticals raised the money through a secondary offering and DiaMedica through a private placement.
- Envoy Medical announced its intent to merge with Anzu Special Acquisition 1 to enter the public markets.

Company	Amount
Lifecore Biomedical	\$150,000,000
ANI Pharmaceuticals	\$86,250,000
<u>DiaMedica</u>	\$37,500,000
Q2/2023 Total	\$273,750,000



## NIH & SBIR/STTR Funding – Q2/2023 Less SBIR/STTR and NIH Funding

- Nine companies received SBIR/STTR grants worth \$5.5 million, a 24% decrease over the previous quarter, and a 72% decrease over the prior year.
- In Q2/2023, Medical Alley companies received over \$146 million from the NIH, with University of Minnesota (\$92 million) and the Mayo Clinic (\$44 million) leading the way. This is a 26% decrease over the previous quarter, and 78% decrease over the prior year.

Organization Name	Projects	Value
Minnesota Healthsolutions Corporation	2	\$1,378,082
Applied Universal Dynamics Corporation	2	\$1,012,520
Innovative Design Labs, Inc.	1	\$884,903
Vergent Bioscience, Inc.	1	\$874,253
Koronis Biomedical Technologies Corporation	1	\$378,331
Neurotype Inc.	1	\$326,672
Elements Endoscopy Inc.	1	\$299,803
Ascan L. L. C.	1	\$276,073
Clairitytek, Inc.	1	\$55,000
Total	11	\$5,485,637

Organization Name	<b>Projects</b>	Value
University of Minnesota	182	\$92,293,431
Mayo Clinic Rochester	80	\$44,230,351
Hennepin Healthcare Research Institute	4	\$8,832,532
HealthPartners Institute	3	\$1,376,011
St. Olaf College	1	\$64,637
Minneapolis VA Medical Center	4	N/A
Total	274	\$146,796,962



#### M&A - Q2/2023

### M&A Transactions – Few and Far Between

- We tracked only six M&A transactions, half of both Q1/2023 and Q2/2022, which corresponds with the continued national trend.<sup>3</sup>
- Only one transaction had publicly available value,
   Medtronic's acquisition of EOFlow for \$738 million.
- It remains to be seen when cash-rich companies will start pulling the trigger on acquisitions. Resetting of valuations to satisfy buyers<sup>4</sup> and market uncertainty being the most cited reasons for the slow down.

#### **Transaction**

Zipnosis acquired by Florence

Sisu Healthcare IT Solutions acquired by Tegria

Libra Medical acquired by RQM+

Innovia Medical acquired by Inverness Graham Investments

**EOFlow acquired by Medtronic** 

Lunaphore acquired by Bio-Techne



## Healthcare Employment – Q4/2022\* Healthcare Jobs Hold Steady

- Healthcare jobs were mostly steady Q-o-Q, with insurance providers being the only category with a notable decrease (-3.5%).
- Y-o-Y, almost all job categories recorded growth.
- In what has become a regular occurrence, the biopharma sector grew the most (+7.7%).
- Providers continue to be the largest healthcare employers in the state, employing 383,000 people.

Industry	Quarterly Average Employment	Q-o-Q Change	Y-o-Y Change
Health Insurance	19,467	-3.5%	1.6%
Medical Device	34,001	-0.7%	3.7%
Other	505	0.1%	4.4%
Pharm/Bio	7,013	0.1%	7.7%
Provider	383,838	-0.8%	1.0%
Retail	15,550	0.5%	-46.7%



<sup>\*</sup> Federal jobs data has a 6-month delay so the most current data in Q2/2023 is for Q4/2022.

### **Contacts**


- Frank Jaskulke, VP of Innovation fjaskulke@medicalalley.org
- Kylle Jordan, Global Principal kjordan@medicalalley.org
- Filip Kostal, Startup Principal <u>fkostal@medicalalley.org</u>
- Reece DeVries, Data Analyst & Engineer rdevries@medicalalley.org





## Appendix

## Medical Alley Starts & Global – Services by Quarter






## Medical Alley Starts & Global – Companies Supported by Quarter






## Medical Alley Starts & Global – Services by Quarter





# Healthcare Private Raises by Quarter – Q2






# Medical Device Private Raises by Quarter – Q2






# Digital Health Private Raises by Quarter – Q2





# Biopharma Private Raises by Quarter – Q2






## **Quarterly Average Employment** in Healthcare – Q4/2022

NAICS Category	Quarterly Average Employment	Q-o-Q % change	Y-o-Y % change
Health Insurance	19,467.33	-3.5%	1.6%
Medical Device	34,001.00	-0.7%	3.7%
Other	505.67	0.1%	4.4%
Pharm/Bio	7,013.00	0.1%	7.7%
Provider	383,838.00	-0.8%	1.0%
Retail	15,550.33	0.5%	-46.7%




# All Healthcare (without Providers) – Quarterly Employment in Minnesota





## Providers – Quarterly Employment in Minnesota






## Medical Device – Quarterly Employment in Minnesota






## Health Insurance – Quarterly Employment in Minnesota





## Biotech & Pharma – Quarterly Employment in Minnesota





## Retail – Quarterly Employment in Minnesota





## Other Healthcare – Quarterly Employment in Minnesota





### References

- 1. Star Tribune: Venture capital investment in Minnesota down 63% in first half of year
- 2. Crunchbase: Al Was Q2's Big Hope To Reverse The Global Venture Funding Slowdown. It Wasn't Enough
- 3. Silicon Valley Bank: State of the Markets H1/2023
- 4. Pitchbook: Global M&A shows resilience as prices drop

